A new milestone in the collaboration between RTM and Quirem Medical

As of the 22nd of May 2018, the Radboud Translational Medicine (RTM) is fully operational for performing the final steps in the manufacturing process of QuiremSpheres. The RTM offers state-of-the-art facilities for the production and processing of radioactive pharmaceuticals and medical devices. Jan Sigger, CEO of Quirem Medical, comments: “It is rewarding to see that the intense collaboration of the team of RTM and our own team over the last months have now led to a seamless introduction of RTM as QuiremSpheres manufacturing site. Through this collaboration we have been able to scale up our manufacturing capacity to meet the anticipated strong increase in demand for our products in the coming years.”

Share this post

Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.


Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.

Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.

This website uses cookies to improve your experience. You can manage your options here.